Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Yakult Honsha Co., LTD.
Recruitment status was Recruiting
Information provided by:
Yakult Honsha Co., LTD
First received: August 11, 2006
Last updated: January 25, 2012
Last verified: January 2012
The purpose of this study is to determine whether IHL-305 (irinotecan liposome injection) is safe and effective in the treatment of advanced solid tumors.
Drug: IHL-305 (irinotecan liposome injection)
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors
Primary Outcome Measures:
- Incidence of dose-limiting toxicity within 28 days of treatment administration for patients with UGT1A1*28 genotype (wt/wt and wt/*28)
- determination of maximum tolerated dose (MTD) and recommended Phase 2 dose for patients with UGT1A1*28 genotype (wt/wt and wt/*28)
Secondary Outcome Measures:
- Tumor shrinkage per Response Evaluation Criteria in Solid Tumors (RECIST) every 8 weeks/2 cycles while receiving study drug for patients with UGT1A1*28 genotype (wt/wt and wt/*28)
- limited pharmacokinetics (PK) for patients with UGT1A1*28 genotype (wt/wt and wt/*28)
- limited incidence and severity of adverse events (AEs) and PK for UGT1A1 homozygous (*28/*28) patients
| Estimated Enrollment:
| Study Start Date:
This is a Phase I dose-escalation study of intravenous administration of IHL-305 in patients with advanced solid tumors. Patients will receive IHL-305 as an intravenous infusion over 60 minutes on Day 1 followed by a 27-day observation period for a total of 28 days (4 weeks) per cycle. Two patient populations will be evaluated separately; patients with UGT1A1*28 genotype homozygous wild-type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Histologically confirmed malignant solid tumor and not a candidate for known regimens or protocol treatments of higher efficacy or priority
- Failed conventional therapy for their cancer or have a malignancy for which a conventional therapy does not exist
- Recovered from all acute adverse effects of prior therapies, excluding alopecia (hair loss)
- ECOG performance status of 0, 1, or 2
- 18 years of age or older
Normal organ and bone marrow function as defined by:
- absolute neutrophil count greater than or equal to 1,500 cells/microliter
- platelets greater than or equal to 100,000 cells/microliter
- total bilirubin within normal institutional limits
- AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal (ULN) or less than or equal to 5.0 x ULN in patients with liver metastases
- plasma creatinine less than or equal to 1.5 x institutional ULN OR
- creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- Ability to understand and the willingness to sign a written informed consent document
- Previously treated with irinotecan, or had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, or not recovered from adverse effects due to agents administered more than 4 weeks earlier
- Receiving any other investigational agent
- Known brain metastases
- History of allergic reactions attributed to compounds of similar chemical composition to IHL-305
- Concurrent serious infections (i.e., requiring an intravenous antibiotic)
- Pregnant women or women of childbearing potential and not using methods to avoid pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential; no breast-feeding while on study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements
- Significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions; history of myocardial infarction within one year of study entry; uncontrolled dysrhythmias; or poorly controlled angina.
- History of serious ventricular arrhythmia (ventricular tachycardia [VT] or ventricular fibrillation [VF], greater than or equal to 3 beats in a row); QTc greater than or equal to 450 msec for men and 470 msec for women; or left ventricular ejection fraction (LVEF) less than or equal to 40% by multi-gated acquisition scan (MUGA).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00364143
|Sarah Cannon Cancer Center
|Nashville, Tennessee, United States, 37203 |
|Principal Investigator: Howard Burris, MD |
|Vanderbilt-Ingram Cancer Center
|Nashville, Tennessee, United States, 37232-6307 |
|Contact: Wendy L. VerMeulen, RN, BSN 615-343-0798 email@example.com |
|Contact: Wendy Cooper, RN, BSN, OCN 615-936-5869 firstname.lastname@example.org |
|Principal Investigator: Mace Rothenberg, MD |
Yakult Honsha Co., LTD
||Mace L Rothenberg, M.D.
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 11, 2006
||January 25, 2012
||United States: Food and Drug Administration
Keywords provided by Yakult Honsha Co., LTD:
Advanced Solid Tumor
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 30, 2015
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors